为保证股权激励计划的顺利实施，现根据《中华人民共和国公司法》《中华 人民共和国证券法》《上市公司股权激励管理办法》等有关法律、法规和规范性 文件、以及公司章程、公司激励计划的相关规定，并结合公司的实际情况，特制 定本办法。 一、考核目的 进一步完善公司法人治理结构，建立和完善公司激励约束机制，保证公司股 权激励计划的顺利实施，并在最大程度上发挥股权激励的作用，进而确保公司发 展战略和经营目标的实现。 二、考核原则 考核评价必须坚持公正、公开、公平的原则，严格按照本办法和考核对象的 业绩进行评价，以实现股权激励计划与激励对象工作业绩、贡献紧密结合，从而 提高公司整体业绩，实现公司与全体股东利益最大化。 三、考核范围 本办法适用于参与公司激励计划的所有激励对象，包括公司公告本激励计划 时在公司（含子公司，下同）任职的董事、高级管理人员、技术和业务骨干人员。 青岛海泰新光科技股份有限公司 2025 年限制性股票激励计划实施考核管理办法 青岛海泰新光科技股份有限公司（以下简称"公司"）为进一步完善公司法 人治理结构，健全公司的激励约束机制，形成良好均衡的价值分配体系，充分调 动公司管理团队和骨干员工的积极性，使其更诚 ...

证券代码：688677 证券简称：海泰新光 公告编号：2025-062 青岛海泰新光科技股份有限公司 关于召开2025年第三次临时股东会的通知 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、 召开会议的基本情况 （一） 股东会类型和届次 2025年第三次临时股东会 （四） 现场会议召开的日期、时间和地点 召开日期时间：2025 年 11 月 10 日 10 点 00 分 召开地点：青岛市崂山区科苑纬四路 100 号公司会议室 （五） 网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东会网络投票系统 网络投票起止时间：自2025 年 11 月 10 日 至2025 年 11 月 10 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东会召开当日的交易时间段，即 9:15-9:25，9:30-11:30，13:00-15:00；通过 互联网投票平台的投票时间为股东会召开当日的 9:15-15:00。 （六） 融资融券、转融通、约定购回业务账户和沪股通投资者的投票程 ...

证券代码：688677 证券简称：海泰新光 公告编号：2025-060 青岛海泰新光科技股份有限公司 第四届董事会第八次会议决议公告 （一）审议通过《青岛海泰新光科技股份有限公司 2025 年第三季度报告》； 具体内容详见公司于上海证券交易所网站（www.sse.com.cn）披露的《青岛 海泰新光科技股份有限公司 2025 年第三季度报告》。 表决结果：7 票同意，0 票反对，0 票弃权。 （二）审议通过《关于公司 2025 年限制性股票激励计划（草案）及其摘要 的议案》； 为进一步激发企业创新创造活力，建立、健全公司长效激励机制，充分调动 核心团队的积极性，吸引和留住优秀人才，有效地将股东利益、公司利益和员工 利益结合在一起，使各方共同关注公司的长远发展，在充分保障股东利益的前提 下，按照收益与贡献对等的原则，根据《中华人民共和国公司法》《中华人民共 和国证券法》《上海证券交易所科创板股票上市规则》《上市公司股权激励管理 办法》《科创板上市公司持续监管办法（试行）》《科创板上市公司自律监管指 南第 4 号——股权激励信息披露》等有关法律、法规和规范性文件以及《公司章 本公司董事会及全体董事保证本公告内容不 ...

青岛海泰新光科技股份有限公司董事会薪酬与考核委员会 关于公司<2025 年限制性股票激励计划（草案）>及其摘要的 核查意见 青岛海泰新光科技股份有限公司（以下简称"公司"）董事会薪酬与考核委员 会依据《中华人民共和国公司法》（以下简称"《公司法》"）《中华人民共和国证 券法》（以下简称"《证券法》"）《上市公司股权激励管理办法》（以下简称"《管 理办法》"）《上海证券交易所科创板股票上市规则》（以下简称"《上市规则》"） 《科创板上市公司自律监管指南第 4 号——股权激励信息披露》（以下简称"《监 管指南》"）等相关法律、法规及规范性文件和《青岛海泰新光科技股份有限公 司章程》（以下简称"《公司章程》"）的有关规定，对公司《2025 年限制性股票 激励计划（草案）》及其摘要进行了核查，发表核查意见如下： 1、公司不存在《管理办法》等法律、法规规定的禁止实施限制性股票激励 计划的情形，包括：（1）最近一个会计年度财务会计报告被注册会计师出具否定 意见或者无法表示意见的审计报告；（2）最近一个会计年度财务报告内部控制被 注册会计师出具否定意见或无法表示意见的审计报告；（3）上市后最近 36 个月 内出现过未按法律 ...

Financial Performance - The company's operating revenue for Q3 2025 reached ¥182,026,942.33, representing an increase of 85.26% compared to the same period last year[3] - The total profit for the period was ¥70,634,060.83, marking a significant increase of 140.41% year-over-year[3] - Net profit attributable to shareholders was ¥61,930,727.98, up 130.72% from the previous year[3] - The net profit excluding non-recurring gains and losses was ¥60,869,867.83, reflecting a 148.40% increase year-over-year[3] - The company reported a basic earnings per share of ¥0.52, which is a 136.36% increase compared to the same period last year[3] - Total operating revenue for the first three quarters of 2025 reached RMB 447.64 million, a significant increase of 40.4% compared to RMB 318.67 million in the same period of 2024[19] - Net profit for the first three quarters of 2025 was RMB 133.32 million, up 38.3% from RMB 96.42 million in the first three quarters of 2024[20] - Basic and diluted earnings per share for the first three quarters of 2025 were both RMB 1.14, compared to RMB 0.81 in 2024, marking a growth of 40.7%[21] - The total profit for the first three quarters of 2025 was RMB 155.56 million, an increase of 42% from RMB 109.59 million in 2024[20] - The company’s total comprehensive income for the first three quarters of 2025 was RMB 132.35 million, compared to RMB 96.35 million in 2024, reflecting a growth of 37.4%[21] Research and Development - Research and development (R&D) expenses totaled ¥18,368,797.26, accounting for 10.09% of operating revenue, a decrease of 6.54 percentage points from the previous year[4] - Research and development expenses increased to RMB 51.58 million in 2025, compared to RMB 47.15 million in 2024, reflecting a growth of 9.2%[19] Cash Flow and Assets - The company experienced a 35.43% increase in net cash flow from operating activities, totaling ¥124,294,919.71 for the year-to-date[3] - The net cash flow from operating activities for the first three quarters of 2025 was RMB 124.29 million, an increase of 35.3% from RMB 91.78 million in 2024[23] - The company reported a net cash increase of RMB 38.38 million in the first three quarters of 2025, contrasting with a decrease of RMB 157.49 million in the same period of 2024[24] Assets and Liabilities - Total assets increased by 9.62% to ¥1,600,568,048.20 compared to the end of the previous year[4] - As of September 30, 2025, the total assets of the company amounted to ¥1,600,568,048.20, an increase from ¥1,460,092,283.49 in the previous year[15] - The company's cash and cash equivalents reached ¥562,193,728.74, up from ¥523,890,835.86 year-over-year[15] - Inventory increased to ¥229,778,396.19 from ¥186,514,537.63, reflecting a growth of approximately 23.1%[16] - Total liabilities rose to ¥283,385,589.73 compared to ¥154,641,332.66 in the previous year, indicating a significant increase[17] - The company's equity attributable to shareholders was ¥1,317,659,571.54, slightly up from ¥1,303,492,801.58[17] - The company reported a total of ¥114,972,424.80 in accounts receivable, a decrease from ¥119,332,508.50[16] - The company has a short-term loan of ¥70,000,000.00, which was not present in the previous year[16] - The company’s long-term investments decreased to ¥42,604,666.89 from ¥53,523,671.16[16] - The company’s total current assets amounted to ¥981,093,687.06, an increase from ¥851,290,383.20[16] Revenue Drivers - The growth in revenue was primarily driven by significant increases in the sales of medical endoscopes and optical products, with both segments showing strong performance[10] Operating Costs - Total operating costs for the first three quarters of 2025 were RMB 281.98 million, up 35% from RMB 208.94 million in 2024[19] Investment Activities - The company experienced an investment cash flow net loss of RMB 74.44 million in 2025, an improvement from a loss of RMB 160.81 million in 2024[24] Shareholder Information - The company has not reported any significant changes in the top ten shareholders or their participation in margin trading[14]

格隆汇10月24日丨海泰新光(688677.SH)公布，公司第三季度实现营业收入1.82亿元，同比增长 85.26%；归属于上市公司股东的净利润6193.07万元，同比增长130.72%；归属于上市公司股东的扣除非 经常性损益的净利润6086.99万元，同比增长148.40%；基本每股收益0.52元。 ...

格隆汇10月24日丨海泰新光(688677.SH)公布2025年限制性股票激励计划，2025年限制性股票激励计划 拟向激励对象授予100万股限制性股票，约占本激励计划草案公告日公司股本总额的0.8342%。其中， 首次授予80万股，约占本激励计划草案公告时公司股本总额的0.6674%，约占本次授予权益总额的 80%；预留20万股，约占本激励计划草案公告时公司股本总额的0.1668%，约占本次授予权益总额的 20%。 ...

Core Viewpoint - Haitai Xinguang (688677.SH) announced a restricted stock incentive plan for 2025, aiming to enhance employee motivation and align their interests with shareholders [1] Summary by Sections Incentive Plan Details - The plan proposes to grant 1 million shares of restricted stock, accounting for approximately 0.8342% of the company's total share capital as of the announcement date [1] - Of the total shares, 800,000 shares will be granted initially, representing about 0.6674% of the company's total share capital at the time of the announcement, which constitutes 80% of the total grant [1] - The remaining 200,000 shares are reserved, making up about 0.1668% of the company's total share capital at the time of the announcement, representing 20% of the total grant [1]

Core Insights - The medical device sector experienced a slight increase of 0.37% on October 24, with Mai Lande leading the gains [1] - The Shanghai Composite Index closed at 3950.31, up 0.71%, while the Shenzhen Component Index closed at 13289.18, up 2.02% [1] Medical Device Sector Performance - Top gainers included: - Mai Lande (688273) with a closing price of 41.92, up 6.31%, trading volume of 29,300 hands, and a transaction value of 121 million yuan [1] - Xiangyu Medical (688626) at 53.21, up 6.10%, with a trading volume of 41,100 hands and a transaction value of 216 million yuan [1] - Xiangsheng Medical (688358) at 35.27, up 4.75%, with a trading volume of 38,400 hands and a transaction value of 136 million yuan [1] - Other notable gainers included: - Aohua Endoscopy (688212) at 50.59, up 4.74%, with a transaction value of 225 million yuan [1] - Weisi Medical (688580) at 49.10, up 4.71%, with a transaction value of approximately 99.8 million yuan [1] Decliners in Medical Device Sector - Notable decliners included: - Chenguang Medical (920300) at 17.51, down 8.80%, with a trading volume of 124,000 hands [2] - Toukeng Life (300642) at 22.95, down 5.40%, with a trading volume of 175,700 hands [2] - Haitai New Light (688677) at 48.50, down 5.05%, with a trading volume of 38,800 hands [2] - Other significant decliners included: - Sino Medical (688108) at 28.00, down 4.73%, with a trading volume of 263,700 hands [2] - Tianchen Medical (688013) at 55.66, down 3.98%, with a trading volume of 19,200 hands [2] Capital Flow in Medical Device Sector - The medical device sector saw a net outflow of 654 million yuan from major funds, while retail investors contributed a net inflow of 455 million yuan [2]

海泰新光(688677)现跌5.05%报48.5元，暂成交1.9亿元，最新市值58亿元。海泰新光公告称，控股股东、实际控制人ZHENGANMIN先生拟减持不超327.8万 股，占公司总股本比例不超2.7345%。减持期间为自公告发布之日起15个交易日后的3个月内，拟减持原因是自身资金需求。(格隆汇) ...